Sign In
Buy PROK
$1.73
-0.170 (-8.95%)
At Close: Jun 03, 2026
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
06:05am, Tuesday, 05'th Sep 2023
WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on pr
Short squeeze alert for September 4th: Two stocks with potential to skyrocket
08:24am, Monday, 04'th Sep 2023
A short squeeze is when traders who heavily short a stock start to cover their short positions by buying back the stock. This increases demand for the stock, and it pushes the price higher, forcing ot
3 Biotech Stocks Due for a Massive Short Squeeze
10:33am, Thursday, 31'st Aug 2023
Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.
ProKidney to Present at the BofA Securities Health Care Conference 2023
06:05am, Thursday, 04'th May 2023
WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (C
ProKidney: Too Many Billionaires, Too Little Data
11:51am, Wednesday, 12'th Apr 2023
ProKidney Corp. has a noble goal - ending kidney dysfunction using cell therapy. It has produced some interesting data from a phase 2 trial.
ProKidney's stock jumps 29%
07:48am, Wednesday, 11'th Jan 2023
Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company's investigationa
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
06:05am, Thursday, 22'nd Dec 2022
WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (
ProKidney to Participate in Upcoming Investor Conferences
04:05pm, Friday, 11'th Nov 2022
WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
06:15am, Friday, 23'rd Sep 2022
WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
06:05am, Thursday, 08'th Sep 2022
WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease
ProKidney to present at upcoming investor conferences
09:00am, Friday, 20'th May 2022
WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the
ProKidney to Present REACT® at 4th Annual CKD Summit
08:05am, Tuesday, 01'st Mar 2022
WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and preve
ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)
03:03pm, Tuesday, 18'th Jan 2022
ProKidney entered into a definitive agreement to become a publicly-traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). These are the details.
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
01:56pm, Tuesday, 18'th Jan 2022
ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III (
ProKidney set to go public after SPAC merger that values combined company at $2.6 billion
07:45am, Tuesday, 18'th Jan 2022
ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC
